Vyacheslav A Korshunov1, Breandan Quinn1, Abrar Faiyaz2, Rifat Ahmed2, Mark P Sowden1, Marvin M Doyley2, Bradford C Berk1,3. 1. Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester, Rochester, New York. 2. Department of Electrical and Computer Engineering, Hajim School of Engineering and Applied Sciences, University of Rochester, Rochester, New York. 3. Neurorestoration Institute, University of Rochester, Rochester, New York.
Abstract
BACKGROUND AND PURPOSE: Sacubitril/valsartan (Sac/val) is more effective than valsartan in lowering BP and mortality in patients with heart failure. Here, we proposed that Sac/val treatment would be more effective in preventing pathological vascular remodelling in 129X1/SvJ (129X1), than in C57BL/6J (B6) inbred mice. EXPERIMENTAL APPROACH: Sac/val (60 mg·kg-1 ·day-1 ) and valsartan (27 mg·kg-1 ·day-1 ) were given as prophylactic or therapeutic treatments, to 129X1 or B6 mice with carotid artery ligation for 14 days. Blood flow was measured by ultrasound. Ex vivo, carotid tissue was analysed with histological and morphometric techniques, together with RNA sequencing and gene ontology. KEY RESULTS: Sac/val was more effective than valsartan in lowering BP in 129X1 compared with B6 mice. Liver expression of CYP2C9 and plasma cGMP levels were similar across treatments. A reduction in carotid thickening after prophylactic treatment with valsartan or Sac/val also resulted in significant arterial shrinkage in B6 mice. In 129X1 mice, Sac/val and prophylactic treatment with valsartan had no effect on carotid thickening but preserved carotid size. BP lowering significantly correlated with a decline in carotid stiffness (R2 = .37, P = .0096) in 129X1 but not in B6 mice. The gene expression signature associated with hyalurononglucosaminidase activity was down-regulated in injured arteries after both regimens of Sac/val only in 129X1 mice. Administration of Sac/val but not valsartan significantly reduced deposition of hyaluronic acid and carotid fibrosis in 129X1 mice. CONCLUSION AND IMPLICATIONS: These results underscore the importance of the genetic background in the efficacy of the Sac/val on vascular fibrosis.
BACKGROUND AND PURPOSE:Sacubitril/valsartan (Sac/val) is more effective than valsartan in lowering BP and mortality in patients with heart failure. Here, we proposed that Sac/val treatment would be more effective in preventing pathological vascular remodelling in 129X1/SvJ (129X1), than in C57BL/6J (B6) inbred mice. EXPERIMENTAL APPROACH: Sac/val (60 mg·kg-1 ·day-1 ) and valsartan (27 mg·kg-1 ·day-1 ) were given as prophylactic or therapeutic treatments, to 129X1 or B6 mice with carotid artery ligation for 14 days. Blood flow was measured by ultrasound. Ex vivo, carotid tissue was analysed with histological and morphometric techniques, together with RNA sequencing and gene ontology. KEY RESULTS: Sac/val was more effective than valsartan in lowering BP in 129X1 compared with B6 mice. Liver expression of CYP2C9 and plasma cGMP levels were similar across treatments. A reduction in carotid thickening after prophylactic treatment with valsartan or Sac/val also resulted in significant arterial shrinkage in B6 mice. In 129X1 mice, Sac/val and prophylactic treatment with valsartan had no effect on carotid thickening but preserved carotid size. BP lowering significantly correlated with a decline in carotid stiffness (R2 = .37, P = .0096) in 129X1 but not in B6 mice. The gene expression signature associated with hyalurononglucosaminidase activity was down-regulated in injured arteries after both regimens of Sac/val only in 129X1 mice. Administration of Sac/val but not valsartan significantly reduced deposition of hyaluronic acid and carotid fibrosis in 129X1 mice. CONCLUSION AND IMPLICATIONS: These results underscore the importance of the genetic background in the efficacy of the Sac/val on vascular fibrosis.
Authors: Rolf Wachter; Daniel Viriato; Sven Klebs; Stefanie S Grunow; Matthias Schindler; Johanna Engelhard; Catia C Proenca; Frederico Calado; Raymond Schlienger; Markus Dworak; Bogdan Balas; Sara Bruce Wirta Journal: Postgrad Med Date: 2018-02-28 Impact factor: 3.840
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: N Engl J Med Date: 2014-08-30 Impact factor: 91.245
Authors: E M de Vries; L A Lammers; R Achterbergh; H-J Klümpen; R A A Mathot; A Boelen; J A Romijn Journal: PLoS One Date: 2016-07-19 Impact factor: 3.240
Authors: Vyacheslav A Korshunov; Breandan Quinn; Abrar Faiyaz; Rifat Ahmed; Mark P Sowden; Marvin M Doyley; Bradford C Berk Journal: Br J Pharmacol Date: 2019-06-24 Impact factor: 8.739
Authors: Vyacheslav A Korshunov; Elaine M Smolock; Mary E Wines-Samuelson; Abrar Faiyaz; Deanne M Mickelsen; Breandan Quinn; Calvin Pan; George J Dugbartey; Chen Yan; Marvin M Doyley; Aldons J Lusis; Bradford C Berk Journal: J Am Heart Assoc Date: 2020-05-12 Impact factor: 5.501